Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/26 11:54:46 am
165.375 USD   +8.41%
10:13aToday on Wall Street: Need help?
09:16aMARKETSCREENER’S WORLD PRESS REVIEW : January 26, 2022
08:07aDeutsche Bank Upgrades Moderna to Hold From Sell, Adjusts Price Target to $175 From $200
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Omicron vaccine warning triggers fresh global selloff

11/30/2021 | 04:39am EST

LONDON, Nov 30 (Reuters) - There was a fall in world share markets and scramble to safer currencies and bonds on Tuesday after the CEO of drugmaker Moderna warned that COVID-19 vaccines are unlikely to be as effective against the new Omicron variant.

Europe's main bourses jolted 1.4% lower early on, oil shed 3%, Australia's currency which is highly sensitive to global economic confidence hit a year low while Japan's safe-haven yen, German government bonds and gold all rose.

"There is no world, I think, where (the effectiveness) is the same level," Moderna's chief Stéphane Bancel told the Financial Times in an interview.

"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to... are like 'this is not going to be good'," Bancel said.

The early tumbles meant Europe's equity markets scratched off Monday's rebound and were below the levels hit on Friday when traders wiped roughly $2 trillion off global stocks in the initial Omicron rout.

Bancel had earlier said on CNBC that there should be more clarity on the efficacy of COVID-19 vaccines against Omicron in about two weeks, but that it could take months to begin shipping a reworked vaccine designed for the new variant.

"It's not good news, and it's coming from someone who should know," said Commonwealth Bank of Australia currency strategist Joe Capurso. "Markets have reacted in exactly the way you'd expect them to"

MSCI's broadest global equities index which tracks 50 countries was 0.2% lower and heading for only its third red month of the year. It has risen nearly 14% in 2021 whereas emerging market stocks have lost nearly 6%.

Risk aversion also hit the currency markets with the U.S. dollar weakening 0.3% versus its main rivals. The Aussie dollar's slide of 0.65% left it at its 12-month low of $0.7093 whereas the Japanese yen - traditionally viewed as safe harbour due to its role as a funding currency - was nearing its highest level of the month at 112.95 yen.

ECONOMIC HIT

There was plenty of data to digest too.

Activity in China's services sector grew at a slightly slower pace in November, official data showed on Tuesday, as the sector took a hit from fresh lockdown measures as authorities raced to contain the latest outbreak.

China's blue chip CSI 300 index closed 0.4% lower while Hong Kong's Hang Seng Index shed over 1.5% exacerbated by breach of a strong technical support level of 24,000 points, according to analysts.

In the commodity markets, Brent crude futures fell $2.32, or 3.2%, to $71.12 a barrel after slipping to the lowest level since Sept. 1.

A bounce in the euro continued though as strong consumer spending boosted Italian GDP data, a day after Germany's inflation rate hit its highest in decades at 6% year-on-year.

Euro zone-wide figures are due shortly. The single currency was last at $1.1350 well up from a near 17-month trough of $1.11864 last week when ECB policymakers signalled they still expected inflation to cool.

Omicron worries though meant the yield on 10-year German Bunds -- regarded as one of the safest assets in the world -- dipped to its lowest in just over a week at -0.345% and was last down about 2 basis points on the day.

Most other benchmark 10-year yields in the euro zone fell by a similar amount, while U.S. 10-year Treasury yields tumbled 7.5 bps to around 1.45%.

"We maintain our view that the ECBs Governing Council will reinforce its patience on the policy rate at the December meeting to look through the inflation surge," analysts at Goldman Sachs said in a note.

"Additional targeted and regional restrictions, rather than blanket lockdowns," will see "a cumulative economic hit over Q4 and Q1 of about 0.4% of GDP in the euro area, and 0.2% of GDP in the UK," they added. Blanket lockdowns though could cause twice as much damage.

(Additional reporting by Scott Murdoch in Hong Kong Editing by Peter Graff)


ę Reuters 2021
All news about MODERNA, INC.
10:13aToday on Wall Street: Need help?
09:16aMARKETSCREENER’S WORLD PRESS REVIEW : January 26, 2022
08:07aDeutsche Bank Upgrades Moderna to Hold From Sell, Adjusts Price Target to $175 From $20..
MT
06:15aINSIDER SELL : Moderna
MT
05:34aANALYST RECOMMENDATIONS : Alphabet, IBM, Meta, Moderna, Netflix...
03:53aCOVID-19 Severity Appears Lower With Omicron, But High Hospitalization Volume Could Str..
MT
03:32aLonza Offers Rosy Outlook After Divisional Growth Leads 2021 Sales To Beat Market Expec..
MT
01:37aLonza's full-year core EBITDA up 20.7% on vaccine demand
RE
01/25US Labor Department's OSHA Revokes COVID-19 Vaccination Order for Large Employers
MT
01/25Prescription drugs, medical devices boost J&J in Q4
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 769 M - -
Net income 2021 11 260 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 5,74x
Yield 2021 -
Capitalization 61 847 M 61 847 M -
EV / Sales 2021 2,81x
EV / Sales 2022 1,80x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 152,54 $
Average target price 265,41 $
Spread / Average Target 74,0%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381
CELLTRION, INC.-19.95%18 444